Retracted: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data

Presenters:

April Armstrong , ¹ Matthias Augustin , ² Andrew Blauvelt , ³ Simone Ribero , ⁴ Esther Serra-Baldrich ⁵

1. University of California Los Angeles, USA
2. University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
3. Blauvelt Consulting, LLC, Annapolis, Maryland, USA
4. University of Turin, Italy
5. Universitat Autònoma de Barcelona, Spain

Disclosure:

Armstrong has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, EPI, Incyte Corporation, Janssen, LEO Pharma A/S, Eli Lilly, Modmed, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Augustin has served as a consultant, lecturer, and researcher and/or has received research grants from companies manufacturing drugs for psoriasis, including AbbVie, Almirall, Amgen, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly, Galderma, Genzyme, GlaxoSmithKline, Hexal, Incyte, Janssen, LEO Pharma, Medac, Menlo, MSD, Mylan B.V., Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Stallergenes, Trevi, and UCB. Blauvelt served as a speaker (received honoraria) for Eli Lilly and UCB; served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, Leo, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, and Union; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka. Ribero received research grants, personal fees, or nonfinancial support from AbbVie, Almirall, Bristol-Myers Squibb, Galderma, LEO Pharma, Eli Lilly, L’Oreal, Novartis, Pfizer, Pierre Fabre, and Sanofi. Serra-Baldrich has received personal fee payments and travel support from Abbvie, Lilly, Sanofi, Novartis, Pfizer, Galderma, and LEO Pharma.

Acknowledgements:

Writing assistance was provided by Nicola Humphry, Nottingham, UK.

Disclaimer:

The opinions expressed in this article belong solely to the authors of the posters.

This content is intended for healthcare professionals. Prescribing information for tralokinumab can be found here. Adverse events reporting information can be found at the end of this article.

Support:

The publication of this article was sponsored by LEO Pharma.

Citation:

EMJ Dermatol. 2025;13[Suppl 2]:2-10. https://doi.org/10.33590/emjdermatol/PRLP5831.

Keywords:

Atopic dermatitis (AD), biologic therapy, chronic, eczema, long-term, systemic therapy, tralokinumab.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.